EGFR and breast carcinoma: Recently, it was reported that anti-EGFR protein-anchored PLGA-PEG NPs (immunonanoparticle, INP) for breast cancer therapy significantly enhanced tumor PTX concentrations by approximately 93-fold, compared to PLGA-PEG NPs and free PTX in athymic mice [94].